BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 23357650)

  • 1. Increased ratio of serum matrix metalloproteinase-9 against TIMP-1 predicts poor wound healing in diabetic foot ulcers.
    Li Z; Guo S; Yao F; Zhang Y; Li T
    J Diabetes Complications; 2013; 27(4):380-2. PubMed ID: 23357650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An MMP/TIMP ratio scoring system as a potential predictive marker of diabetic foot ulcer healing.
    Luanraksa S; Jindatanmanusan P; Boonsiri T; Nimmanon T; Chaovanalikit T; Arnutti P
    J Wound Care; 2018 Dec; 27(12):849-855. PubMed ID: 30557113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases and diabetic foot ulcers: the ratio of MMP-1 to TIMP-1 is a predictor of wound healing.
    Muller M; Trocme C; Lardy B; Morel F; Halimi S; Benhamou PY
    Diabet Med; 2008 Apr; 25(4):419-26. PubMed ID: 18387077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dynamic changes of MMP-1, MMP-9 and TIMP-1 in the refractory diabetic dermal ulcers treated by autologous Platelet-rich gel].
    He LP; Wang C; Chen DW; Li XJ; Ran XW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 43(5):757-61. PubMed ID: 23230755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Protein expressions of matrix metalloproteinase-9 and its inhibitor and their ratio changes in wound healing of patients with stages Ⅲ and Ⅳ pressure ulcers].
    Wang Y; Li X; Zhao W; Gao ZZ; Zheng MJ; Pang YL; Chen ZY
    Zhonghua Shao Shang Za Zhi; 2019 Oct; 35(10):746-751. PubMed ID: 31658546
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma.
    Ulrich D; Noah EM; von Heimburg D; Pallua N
    Plast Reconstr Surg; 2003 Apr; 111(4):1423-31. PubMed ID: 12618601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
    Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers.
    Liu Y; Min D; Bolton T; Nubé V; Twigg SM; Yue DK; McLennan SV
    Diabetes Care; 2009 Jan; 32(1):117-9. PubMed ID: 18835949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers.
    Mwaura B; Mahendran B; Hynes N; Defreitas D; Avalos G; Adegbola T; Adham M; Connolly CE; Sultan S
    Eur J Vasc Endovasc Surg; 2006 Mar; 31(3):306-10. PubMed ID: 16169261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux].
    Taranta-Janusz K; Zoch-Zwierz W; Wasilewska A; Tenderenda E; Korzeniecka-Kozerska A
    Pol Merkur Lekarski; 2010 Aug; 29(170):88-92. PubMed ID: 20842819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients.
    Lobmann R; Ambrosch A; Schultz G; Waldmann K; Schiweck S; Lehnert H
    Diabetologia; 2002 Jul; 45(7):1011-6. PubMed ID: 12136400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
    Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
    Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia].
    Krawczuk-Rybak M; Kuźmicz M; Mroczko B; Szmitkowski M
    Pol Merkur Lekarski; 2010 Jul; 29(169):14-8. PubMed ID: 20712241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors in women with glucose intolerance in pregnancy and normal controls.
    Stojanovic N; Lewandowski K; Salata I; Bienkiewicz M; Tuck S; Prelevic G; Press M
    Gynecol Endocrinol; 2010 Mar; 26(3):201-7. PubMed ID: 19526397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers: Response to Liu et al.
    Muller M; Trocme C; Morel F; Halimi S; Benhamou PY
    Diabetes Care; 2009 Nov; 32(11):e138. PubMed ID: 19875601
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.